2020
Patterns of oral anticoagulation use with cardioversion in clinical practice
Geurink K, Holmes D, Ezekowitz MD, Pieper K, Fonarow G, Kowey PR, Reiffel JA, Singer DE, Freeman J, Gersh BJ, Mahaffey KW, Hylek EM, Naccarelli G, Piccini JP, Peterson ED, Pokorney SD. Patterns of oral anticoagulation use with cardioversion in clinical practice. Heart 2020, 107: 642-649. PMID: 32591363, DOI: 10.1136/heartjnl-2019-316315.Peer-Reviewed Original ResearchConceptsStroke/transient ischemic attackVitamin K antagonistsNovel oral anticoagulantsTransient ischemic attackTransoesophageal echocardiogramAtrial fibrillationClinical practiceAtrial Fibrillation IIOral anticoagulation useTime of cardioversionBetter Informed TreatmentMonths of enrollmentIncidence of deathLow-risk procedureSimilar ratesAnticoagulation useIschemic attackMajor bleedingK antagonistsOral anticoagulantsClinical outcomesOutcomes RegistryCardiovascular hospitalisationAF diagnosisInclusion criteria
2018
Underuse of Vitamin K Antagonist and Direct Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A Contemporary Review
Hsu JC, Freeman JV. Underuse of Vitamin K Antagonist and Direct Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A Contemporary Review. Clinical Pharmacology & Therapeutics 2018, 104: 301-310. PMID: 29328506, DOI: 10.1002/cpt.1024.Peer-Reviewed Original ResearchConceptsAtrial fibrillationStroke preventionVitamin K antagonistsDirect oral anticoagulantsNonvalvular AF patientsOral anticoagulant therapyRisk of strokeSpecial patient populationsSerious clinical problemOAC therapyK antagonistsOral anticoagulantsAnticoagulant therapyAF patientsPatient populationLeading causeClinical problemPatientsSignificant deleterious impactPreventionFibrillationTherapyContemporary reviewStrokeUnderuse
2012
Cost-effectiveness of pharmacologic and invasive therapies for stroke prophylaxis in atrial fibrillation
Solomon MD, Ullal AJ, Hoang DD, Freeman JV, Heidenreich P, Turakhia MP. Cost-effectiveness of pharmacologic and invasive therapies for stroke prophylaxis in atrial fibrillation. Journal Of Cardiovascular Medicine 2012, 13: 86-96. PMID: 22193838, DOI: 10.2459/jcm.0b013e32834f23cf.Peer-Reviewed Original ResearchConceptsCost-effectiveness analysisAtrial fibrillationNonpharmacologic therapiesAtrial fibrillation-related strokeVitamin K antagonistsNew pharmacologic therapiesDirect thrombin inhibitorDevice-based therapiesLeft atrial appendageStroke Risk ProfileHealth policy recommendationsPercutaneous ligationStroke prophylaxisK antagonistsStroke preventionPharmacologic therapySurgical ligationAbnormal heart rhythmAntiplatelet agentsProphylaxis strategiesAtrial appendageRight atriumEndovascular implantationInvasive therapySystemic circulation